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Abstract 
Naratriptan (NAR) is currently used for the management of migraine as the 
hydrochloride salt (NAR.HCl) and is administered as an oral tablet. This work evaluates the 
feasibility of buccal delivery of NAR in order to ensure faster onset of action and avoid the 
side-effects associated with conventional oral formulations. We hypothesised that the 
unionised form of NAR would permeate buccal tissue to a greater extent than the salt. 
Therefore the first stage of this work required preparation of the free base from NAR.HCl. 
Characterisation of the base with thermal and elemental analyses confirmed its purity; Log P 
and Log D values were also determined. The pH permeation profile of NAR was also 
determined in the range 7.4 – 10.  Solubility studies in non-aqueous solvents indicated that 
Transcutol™ (TC) and dipropylene glycol (DPG) were suitable vehicles for the free base. 
Maximum amounts of NAR which permeated after 6 h were ~130 µg/cm2. Based on the pH 
permeation results and studies conducted at two different doses NAR appears to permeate 
porcine buccal tissue via the transcellular route. Finally, estimates of likely systemic values 
suggest that optimised formulations should be taken forward for in vivo evaluation.   
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1. Introduction 
Naratriptan (NAR), a 5-hydroxy tryptamine agonist, is used in the treatment of acute 
phase migraine as the hydrochloride salt (NAR.HCl). The drug is administered orally as a 
conventional tablet (1). Unfortunately, formulations currently available are not associated 
with good patient compliance because of related gastrointestinal adverse reactions (2). Buccal 
drug delivery (BDD) may offer an alternative route for administration of NAR with minimal 
side effects. This requires the active to permeate through the buccal epithelium in sufficient 
amounts to achieve effective therapeutic plasma concentrations. Orally disintegrating tablets 
of NAR.HCl were prepared and characterised by Stange et al. (3). However the ability of 
these preparations to deliver the drug across buccal tissue was not evaluated.  
The penetration of a molecule through the hydrophilic and lipophilic domains of the 
buccal tissue depends largely on its physicochemical properties (4,5). Molecules, which are 
administered transdermally, have also been developed as commercial oral transmucosal 
preparations (6). This suggests that the desirable properties for buccal delivery are similar to 
those for drugs delivered transdermally for systemic effects. Typically these include low 
melting point, molecular weight (MW) < 500 and balanced log P values (7). Ionisation will 
also influence permeation; greater transmucosal permeation has been observed for the 
unionised forms of a number of actives compared with their salts (8-10). Holm et al. (11) 
demonstrated pH-dependent permeation for metoprolol both in vitro and in vivo using porcine 
models with greater permeation at higher buffer pH values.  
The aims of the present work were therefore to: 
(i) Prepare and characterise NAR base from the salt form.  
(ii) Determine the solubility and stability of NAR in a range of candidate 
vehicles.  
(iii) Compare the buccal permeation characteristics of the base with the salt 
using an in vitro porcine buccal model.  
 
2. Materials and Methods 
2.1 Materials 
NAR HCl was obtained from Bioprogress (March, UK). Ethanol (ET), 99.7–100% 
(v/v) AnalaR® grade was supplied by VWR (UK). Transcutol P® (TC), Labrafac PG®, 
Labrafac WL® and propylene glycol monolaurate (PGML) were gifts from Gattefossé (St. 
Priest, France). Oleic acid (OA) and polyethylene glycol 400 (PEG 400) were purchased 
from Fluka (Germany). Dipropylene glycol (DPG) and n-octanol were purchased from Acros 
Organics (USA). Miglyol® 812 N (MG) was obtained from Sasol (Germany). Isopropyl 
myristate (IPM) and isopropyl palmitate (IPP) were obtained from Croda Ltd (UK). Ethyl 
acetate, sodium hydroxide (NaOH) and Krebs-Ringer bicarbonate buffer (KRB) were 
obtained from Sigma-Aldrich (Germany). Polyethylene glycol 200 (PEG 200), propylene 
glycol (PG), phosphate buffered saline (PBS), HPLC grade acetonitrile (ACN), 
trifluoroacetate (TFA) and water were all obtained from Fisher Scientific (UK). Porcine 
buccal tissue was obtained from a local abattoir immediately after slaughter and transported 
on ice. Caffeine (50 µg/ml in KRB) was used as a marker molecule to evaluate the integrity 
of the buccal tissue and permeation was monitored up to 6 h.  
 
2.2 Preparation of NAR base 
NAR.HCl was converted to the base form (Figure 1) by a simple acid-base reaction. 
NaOH (0.1M) was added slowly to an aqueous solution of the salt with gradual mixing. The 
precipitate was then removed by filtration (Whatman grade filter paper No.52, UK) and 
washed with distilled water. Two methods were used to collect the precipitate: (i) Drying 
over silica gel in a desiccator for 2 days at room temperature, or (ii) Dissolution in ethyl 
acetate and incubation overnight at 40ºC to recrystallise the base. The final products were 
stored in airtight containers at 5ºC. 
 
2.3 Thermogravimetric analysis (TGA) and Differential scanning calorimetry (DSC) 
Thermogravimetric analysis (TGA, Hi-Res 2950, TA Instruments, USA) was used to 
monitor the mass changes of the salt and base as a function of increasing temperature. This 
was performed in open aluminum hermetic pans with a heating rate of 10°C/min, from 35 - 
300°C. Differential Scanning Calorimetry (DSC, Q2000, TA instruments, USA) was used to 
determine the melting point and purity of the salt and base. The DSC was calibrated using 
indium with a heating rate of 10°C/min over the temperature range from 35 - 275°C under 
dry nitrogen purging (50 mL/min) using hermetically sealed pans. 
 
2.4 Elemental analysis and Liquid Chromatography Mass Spectrometry (LC-MS) 
The salt and the base were analysed to determine the carbon, hydrogen and nitrogen 
content using an Elemental Analyser (Carlo-Erba, EA 1108, Italy). LCMS (Alliance 2695 
Separations module with Micro mass ZQ Mass Detector 2996 Photodiode Array Detector, 
Waters, Ireland) was used to determine the purity of both species when dissolved in 
methanol. The chromatographic column was an Onyx™ Monolithic C18, LC Column (50 x 
4.6 mm). The volume of injection was 10 µL and the column was maintained at 35ºC. The 
flow rate was 1.5 mL/min, and the run time was 10 min. A gradient method was used for 
analysis with the mobile phase consisting of 0.1% formic acid in water and acetonitrile.  
 
2.5 High Performance Liquid Chromatographic (HPLC) analysis  
A stock solution of 100 µg/mL of NAR in water was used to prepare a series of 
concentrations ranging from 0.5 - 30 µg/mL. These standards were used to construct a 
calibration curve for HPLC analysis (Agilent 1100, USA operated with ChemStation® 
software). A Phenomenex PhenoSphere™ CN 80 Å (250 × 4.6 mm, 5 µm) fitted with a C18 
cartridge (20 × 4.6 mm, 5µm) was used for analysis. Ultraviolet (UV) detection at 284 nm 
was employed; the injection volume was 10 µL and the column temperature was maintained 
at 40ºC. The mobile phase solution consisted of 0.1% TFA in water with ACN (78:22, v/v). 
The flow rate was 1 mL/min, and the run time was 8 min. Under these conditions, NAR 
exhibited a retention time of 5.4 ± 0.1 min. The HPLC method was validated in terms of 
specificity, linearity, accuracy, precision, detection limit and quantification limit according to 
International Conference of Harmonization guidelines (12). The limit of detection was 0.23 
µg/mL while the limit of quantification was 0.7 µg/mL. 
 
2.6 Solubility studies, solubility parameter and stability  
For solubility determination in candidate vehicles an excess amount of NAR was 
added to one mL of solvent in a reaction tube and sonicated for five minutes. The suspensions 
were kept at 37ºC for 2 days with continuous rotation. Thereafter, the tubes were centrifuged 
and 50 µL of the clear supernatant was diluted and quantified by HPLC. Experiments were 
performed in triplicate and mean values with standard deviations (SD) were calculated 
(13,14). To determine solubility at different pH values, excess NAR was added to PBS to 
which a few drops of 0.1M HCl or 0.1M NaOH were added to obtain the required pH value. 
Suspensions were stirred for 48 h at room temperature. The pH was measured using a 
SympHonyTM pH meter (SB70P, VWR, Germany) and corrected with 0.1M HCl or 0.1M 
NaOH to the required pH value at 24 and 48 h. Suspensions were centrifuged for 15 min at 
13200 rpm. Finally, the supernatant was diluted and quantified by HPLC. Experiments were 
performed in triplicate and mean values with SD were calculated. The relative composition of 
each NAR micro-species in solution as a function of pH was calculated using Equations 1 – 3 
(15).  
 Equation 1 
 
 Equation 2 
 
 Equation 3 
 
Where NAR+, NAR, NAR- are NAR micro species, [H+] is hydrogen ion concentration, 
and Ka1, Ka2 are the dissociation constants. 
The short term stability of NAR in various solvents was determined by preparing 
solutions with concentrations equal to 30% of their original solubility. The solutions were 
kept at 37ºC for 3 days with continuous rotation and samples were analysed by HPLC at time 
zero and at 24 h intervals. The percentage of NAR remaining versus time was determined. 
The study was conducted in triplicate. The three dimensional solubility parameters (δ) of the 
drug and vehicles were calculated according to the Van Krevelen 3-D approach utilising 
Molecular Modeling Pro® software (Chem SW, Inc., USA).  
 
2.7. Determination of partition (log P) and distribution coefficients (log D)  
For the determination of log P, octanol pre-saturated with water and water pre-saturated 
with octanol was achieved by mixing 50 mL of each solvent in a conical flask, followed by 
stirring for 48 h. A modification of the method reported by Birudaraj et al. (10) was used to 
measure Log D and octanol was saturated with the PBS adjusted as described in the previous 
section. A stock solution of 0.1 mg/mL of NAR in the saturated octanol layer was prepared 
and mixed with the saturated aqueous layer; three different ratios of octanol:water or pH 
adjusted PBS were studied (1:1, 1:2, 2:1). Tubes were agitated 100 times over 5 min and 
allowed to stand for 48 h (16). A sample from each phase was diluted and analysed by HPLC. 
The log of the partition coefficient or distribution coefficient was calculated using the relative 
NAR concentrations in n-octanol / water or n-octanol / pH adjusted PBS. All measurements 
were conducted at room temperature and in triplicate. 
 
2.8 In vitro permeation experiments  
Porcine buccal tissue was obtained from a local abattoir immediately after slaughter 
and was transported on ice. All experiments were conducted with fresh tissue. The buccal 
mucosa was separated from the underlying tissues with surgical scissors and a scalpel blade. 
The mucosa was trimmed using a dermatome to a thickness of 0.8 ± 0.1 mm. Tissue was cut 
to suitable dimensions and mounted in Franz diffusion cells. The diffusional area was ~1 cm2 
(the diameters for each cell were measured accurately). Approximately 5 ml of PBS (pH 7.4) 
was used as the receptor phase after degassing with high speed stirring under a vacuum for 20 
min in a Nuova II stirrer (Thermolyne, USA) connected to a vacuum pump. Cells were 
placed in a water bath set at 37ºC and 1 mL of PBS was added to the donor chamber for 30 
min to ensure tissue hydration and to mimic as best as possible the conditions in the mouth. 
The temperature of the cells was routinely measured with a thermometer (Corby, UK) until 
all cells were at 37 ± 0.5ºC. Donor PBS was removed immediately before the addition of any 
formulations. The test solution (100 µL) was then added to the donor chamber. Permeation 
experiments were conducted under occlusion by covering the donor compartments with 
Parafilm™. A volume of 200 µL was withdrawn from each receptor chamber at specific time 
intervals and replaced with an equal volume of warm fresh degassed PBS. Three to five 
experiments were conducted for each formulation. NAR.HCl was dissolved in water, PG, TC, 
PEG 200, or PEG 400 at a concentration of 2.5 mg/mL and 1 mL was applied to the donor 
chamber. NAR was dissolved in TC and DPG at concentrations of 2.5 mg/mL and 25 mg/mL 
(as the current therapeutic dose is 2.5 mg) to study the effect of dose on NAR buccal 
delivery; 100 µL was applied in the donor chamber. To study the influence of pH on NAR 
buccal delivery, the donor chamber was charged with 1 mL of saturated drug solution in PBS 
(pH= 7.4, 8.5, 9.5, and 10). The cumulative amount of drug permeated per unit area of buccal 
mucosa (µg/cm2) was plotted against the collection time (6 h) and reported as Q6h; the slope 
of this graph at the steady state was considered as the flux (Jss) and the extrapolated x-axis 
intercept as the lag time (tlag). The permeability coefficient (kp) was determined as reported 
previously (17).  
Mass balance studies were conducted to quantify the amount of drug in the different 
compartments of the Franz cells as well as in the tissue. Initially, the remaining amount of 
formulation on the tissue was pipetted out, diluted and analysed using HPLC. Secondly, the 
surface of the membrane was washed three times sequentially with 1 mL of methanol:water 
(50:50, v/v). Finally, the cells were disassembled and the buccal membranes were cut into 
small pieces and incubated in 5 mL of methanol:water (50:50, v/v) at 37ºC with 12 h of 
shaking in order to extract any remaining drug inside the tissue. Buccal washes and extracts 
were centrifuged for 20 min at 13.2 (×1000) rpm (Eppendorf centrifuge, UK) and a sample of 
the supernatant was diluted and analysed by the HPLC. The final cumulative amount of drug 
permeated was used to calculate the recovery of the drug in the receptor phase. Validation of 
the washing and extraction procedure was conducted and results confirmed 97.5±1.4% 
recovery of the applied active for the washing procedure and 96% recovery for the extraction 
step.  
 
2.9 Statistical analysis 
The data were analysed using a software package (SPSS version 22) and Excel 
(Microsoft Office 2010). All results are presented as mean ± standard deviation (SD). The 
Student's t-test and one-way analysis of variance (ANOVA) with replication using the Post 
Hoc Tukey test were used to investigate statistical differences. A probability of p < 0.05 was 
considered statistically significant.  
3. Results and Discussion  
3.1 Thermal, elemental and LC-MS analyses  
The molecular weight and the melting point for NAR (Figure 1) are 335.4 g/mole and 
170° to 171°C and the corresponding values for NAR.HCl are 371.9 g/mole and 237° to 239° 
C, respectively (18). NAR base prepared following drying had the appearance of a white 
powder. Visual inspection suggested that the precipitate collected after dissolution in ethyl 
acetate and evaporation was crystalline. The percentage yield of the resultant precipitate was 
78 ± 5 %, with some of the drug likely being lost during the washing steps. Figure 2 shows 
the thermograms for the salt and the base prepared from aqueous solution or from ethyl 
acetate. The precipitate recrystallised from ethyl acetate shows a thermal curve similar to that 
for the salt with a gradual slope around 170°C (near the melting point of NAR base). 
However the thermogram of the base prepared without ethyl acetate indicates the presence of 
some residual water molecules in the sample. DSC analysis was consistent with the TGA 
results. Figure 3 shows the DSC scan for the salt and the base prepared from ethyl acetate. 
The melting point for NAR.HCl is 248°C and this peak was absent in the thermogram of the 
base, which clearly indicated the complete conversion of the salt to the base. The presence of 
a single endothermic sharp peak confirmed that the entire drug was converted to a form with 
a melting point of 178ºC. CHN analysis indicated good agreement between the practical and 
theoretical mass fractions of C, H and N atoms in NAR.HCl, and in the base prepared from 
ethyl acetate. A single peak was obtained for the LCMS analysis confirming the purity of the 
sample. This sample was used in all subsequent studies because of the residual water in the 
product recrystallised from the aqueous solution.  
 
3.2 Solubility, solubility parameter and stability results 
Solubility and stability studies were conducted in a range of solvents commonly used 
in topical and transdermal preparations (Figure 4). NAR was noted to be stable in all the 
tested solvents when incubated at 37ºC for 3 days. The solubility parameter (δ) of NAR was 
calculated to be 12.52 (cal/cm3) 0.5. NAR shows the highest solubility in TC which has a δ 
value of 10.62 (cal/cm3) 0.5.  High solubility was also observed in DPG, ET and PEG 200 with 
corresponding δ values of 12.19, 12.26 and 12.06 (cal/cm3) 0.5. Lowest solubility was 
observed for the solvents with δ values in the range of 7-9 (cal/cm3) 0.5 which included MG, 
IPM, IPP, Labrafac PG® and Labrafac WL®, with the exception of OA. The higher solubility 
in OA may reflect association of the positive charge of the tertiary amine group of NAR and 
the carboxylic acid moiety of OA. The maximum solubility of NAR.HCl was determined in 
water (27.3 ± 0.5 mg/mL) followed by PG (14.9 ± 0.4 mg/mL), PEG 200 (10.9 ± 0.6 
mg/mL), PEG 400 (3.1 ±0.1 mg/mL) and TC (1.0 ± 0.1 mg/mL).  
 
3.3 Partition and distribution coefficients 
The average log P of NAR for the three octanol:water ratios investigated was 
determined to be 0.63 ± 0.08 with a total drug recovery of 96.7% ± 1.7. NAR has two 
different pKa values as a result of (i) A basic piperidine ring - pKa 9.6, and (ii) An acidic 
sulfamide group - pKa 10.6. At pH 10 around 60% of NAR is present in the unionised form 
and the drug shows the highest log D and lowest solubility, while at physiological pH (6.8 to 
7.4) the situation is reversed. Figure 5 shows the change in Log D value as a function of pH 
with solubility values of NAR ranging from 16.8 mg/ml at pH 7.4 to 0.3 mg/ml at pH 10.   
 
3.4 In vitro permeation studies 
Single solvents  
Permeation studies conducted with caffeine confirmed the integrity of all tissues (data 
not shown). No permeation of NAR.HCl was observed from an aqueous solution (2.5 
mg/mL) and at the same concentrations in PG, PEG 200, PEG 400 and TC. The results of the 
mass-balance studies for PG, PEG 200, PEG 400 and TC confirmed that more than 95% of 
the applied doses of NAR.HCl were recovered from the membrane surface and less than 2% 
was extracted from the tissue. The extracted amount of NAR.HCl for the various solvents 
may be ranked as follows: PG > TC > PEG 200 > PEG 400.   
Permeation studies for NAR were conducted in the two solvents for which NAR 
exhibited the highest solubility. The permeation profiles for two concentrations of NAR in 
TC and DPG (2.5 mg/ml and 25 mg/ml) across porcine buccal mucosa over 6 h are shown in 
Figure 6; permeation parameters are summarised in Table 1. Lag times (tlag) ranged from 165 
to 213 min and are comparable to values reported for other studies with porcine buccal tissue 
(19). However, the thickness of the tissue will also influence the magnitude of this parameter 
(20). Steady state flux and cumulative permeation values were significantly higher (p<0.05) 
for NAR in TC compared with NAR in DPG for both doses investigated. TC (diethylene 
glycol monomethyl ether) is used in the formulation of cosmetics and pharmaceuticals and 
manufacture of food additives because of its excellent solvent properties (21).  It is also used 
as a skin penetration enhancer (22). Similarly, DPG is used in both cosmetic and 
pharmaceutical products for its solvent and humectant capabilities (22) but only limited data 
are available for its use or administration via the oral route. NAR permeated in a 
concentration-dependent manner from both solvents as the flux values and the cumulative 
amount permeated increased proportionally with the dose (Figure 6, Table 1). These findings 
are consistent with NAR permeation across the buccal mucosa being a passive diffusion 
process.  
 
pH permeation studies  
To understand the influence of pH on NAR buccal delivery, the permeability was 
determined in phosphate buffer saline (PBS) in the pH range 7.4 - 10. This range was selected 
to encompass the pKa value associated with the piperidine ring of NAR (9.6). The permeation 
profiles (expressed as percentage of applied dose) over 8 h following application of 1 mL of 
saturated solutions of NAR are shown in Figure 7. Figure 7 clearly shows that solutions with 
a higher pH value resulted in a higher percentage of tissue penetration with more rapid 
permeation across the buccal mucosa. The percentage permeation of NAR for the pH 10 
solution was significantly greater than for solutions with lower pH values (ANOVA, p < 
0.05). Results for mass balance studies are shown in Figure 8. The permeation profiles are 
consistent with the mass balance studies where the amount of NAR deposited in the buccal 
membrane was also pH-dependent. The increase in drug-tissue content at higher pH values is 
consistent with the increase in the distribution coefficient. Table 2 summarises NAR 
permeability coefficients, percentages permeated over 8 h, unionised fractions and 
distribution coefficients for the pH range studied. Although tissue integrity was not evaluated 
at the end of these permeation experiments, other researchers report no epithelial changes for 
experiments conducted with excised porcine tissue in the pH range 7.4 – 9.0 (23). These 
authors also reported no significant differences in lag times for mannitol permeation for 
studies conducted at pH 7.4 compared with pH 9.0; surprisingly, lag times for studies 
conducted at pH 8.5 were significantly longer than for pH 7.4.  
The permeability coefficient (kp) of NAR increased significantly (ANOVA, p < 0.05) 
with pH. A seven-fold increase in the buccal permeability coefficient and a ten-fold increase 
in the percentage of drug which permeated were observed over the pH range studied. The 
increase in the kp values and the fraction of NAR permeated after 8 h at the higher pH values 
are in line with the increase of the fraction of unionised species and the calculated 
distribution coefficients. There are two major routes for drug permeation through the buccal 
mucosal membrane: paracellular and transcellular (24). It has also been suggested that if the 
drug is transported through the paracellular route (without partitioning), pH should not affect 
drug absorption rate. For the transcellular pathway the drug absorption rate is pH dependent. 
Porcine buccal tissue has been used to model oral transmucosal delivery of a wide 
range of drug molecules in vitro (6). Histological features of porcine buccal tissue are 
reported to be similar to those of humans as well as its permeability to water (25,26). The 
influence of various experimental variables on drug permeation in such ex vivo models has 
also been studied extensively (20, 27-28). Recently, the relationship between drug permeation 
in ex vivo porcine and human buccal tissue models has also been explored (23). Although 
porcine tissue was approximately two-fold more permeable to metoprolol than human tissue a 
good correlation between the two models was observed (r2=0.96). Histomorphological 
examination also confirmed similar features for tissue from the two species.  
The maximum amount of NAR which permeated after 6 h was ~130 µg/cm2 when 
dosed at 25 mg/ml in Transcutol™ (100 µl application). The mean plasma concentration and 
clearance values of NAR following oral administration are reported as 8 µg/L (ranging from 
5.9-10.7 µg/L) and 6.6 mL/min/kg (18). Assuming a 70 kg patient and calculating NAR input 
from the flux values in Table 1, a plasma level of 1.8 µg/L of NAR is possible from an area 
of application of 1 cm2. Although this falls below the mean therapeutic plasma values 
reported for humans, an application area of 4.4 cm2 should theoretically result in a plasma 
concentration of 8 µg/L. 
4. Conclusions 
NAR was prepared and characterised from its hydrochloride salt; Log D and Log P values 
were also determined. Solubility and stability screening was conducted for a range of single 
solvents. Although no buccal permeation was observed for NAR.HCl this is the first report of 
buccal permeation of NAR. There is scope to optimise further these simple vehicles for 
buccal delivery which will be explored in a future paper. NAR permeated porcine buccal 
tissue in a concentration-dependent manner which suggests NAR permeates buccal mucosa 
via a passive diffusion process. Permeability experiments and mass balance studies showed 
that NAR permeated the buccal mucosa more favourably as the unionised form. The pH 
dependent permeability of NAR provides further support for the transcellular pathway being 
the primary route of transport of the molecule. Finally, differences in permeability 
characteristics of porcine and human buccal tissue are acknowledged however the in vitro 
porcine model appears to offer the closest alternative to studies with tissue from invasive 
biopsies in humans. 
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Table 1: NAR permeation parameters for in vitro permeation experiments in TC and 
DPG when dosed at 2.5 mg/mL and 25 mg/mL (n>3, mean±S.D.) 
 
TC DPG  
NAR 
2.5 mg/mL 
NAR 
25 mg/ml 
NAR 
2.5 mg/mL 
NAR 
25 mg/ml 
Jss 
(µg/cm2/min) 0.09 ± 0.05 0.83 ± 0.39 0.022 ± 0.001 0.23 ± 0.01 
tlag (min) 207.7 ± 16.7 211.3 ± 12.3 164.9 ± 35.8 213.1 ± 16.4 
kp *10-6 
(cm/min) 35.6 ± 20.8 33.4 ± 15.7 8.9 ± 3.8 9.2 ± 0.5 
Q6h (µg/cm2) 13.5 ± 7.1 127.1 ± 60.2 4.4 ± 1.6 38.9 ± 5.5 
 
Table 2: NAR unionised fraction, Log D, kp and percentage permeated after 8 h for 
saturated solutions of varying pH 
 
pH Unionised 
Fraction 
Log D kp (cm/s) *107 Percentage 
permeated (%) 
7.4 0.8 -0.15 ± 0.01 4.9 ± 1.4 2.7 ± 1.1 
8.5 9.1 0.26 ± 0.02 9.6 ± 2.1 5.0 ± 1.1 
9.5 48.1 0.67 ± 0.04 15.1 ± 5.8 9.3 ± 4.2 
10 63.8 1.15 ± 0.09 34.2 ± 10.8 27.6 ± 5.1 
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Figure 1: Chemical structure of NAR 
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Figure 2: TGA thermograms of NAR.HCl, base prepared from ethyl acetate and base 
prepared from aqueous solution  
  
Figure 3: DSC thermogram of NAR.HCl and NAR recrystallised from ethyl acetate 
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Figure 4: Solubility of NAR in various solvents at 37oC (n= 3, Mean ± S.D.) 
 Figure 5: Log D of NAR as a function of pH  
 
 Figure 6: Cumulative amount (µg/cm2) naratriptan permeated for 2.5 mg/mL or 25 
mg/mL solutions in TC and DPG (n ≥ 3, mean ± SD) 
 Figure 7. Percentage of NAR permeation from saturated solutions of pH values 7.4 – 10 
over 8 h (n=5, mean± SD) * denotes significant differences (p < 0.05) 
 Figure 8. NAR mass balance studies for permeation studies of saturated drug in PBS for 
the pH range 7.4 – 10 (n=5, mean ± SD); * denotes significant differences (p < 0.05)  
 
 
 
 
